Common Contracts
5 similar Underwriting Agreement contracts by Cemtrex Inc, Cyngn Inc., Sunshine Biopharma, Inc, Volcon, Inc.
Underwriting AgreementUnderwriting Agreement • May 3rd, 2024 • Cemtrex Inc • Electronic components & accessories • New York
Cemtrex Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 11,764,705 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.001 par value per share (the “Closing Shares”) of the Company (the “Common Stock”) and one (1) Series A warrant (each, a “Series A Warrant”) to purchase one (1) share of Common Stock at a per Share exercise price of $0.85 and one (1) Series B warrant (each, a “Series B Warrant”) to purchase one (1) share of Common Stock at a per Share exercise price of $0.85 (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price of $0.001 and one (1) Series A Warrant and one (1) Series B Warrant (each, a “Closing Pre-funded Unit”). The shares of Common
Underwriting AgreementUnderwriting Agreement • April 23rd, 2024 • Cemtrex Inc • Electronic components & accessories • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • April 23rd, 2024 • Cyngn Inc. • Services-computer programming services • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2024 • Sunshine Biopharma, Inc • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • November 20th, 2023 • Volcon, Inc. • Motor vehicles & passenger car bodies • New York
Volcon, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) (i) an aggregate of 42,857,142 common units (“Common Units”), each consisting of one share of common stock (the “Firm Shares”), par value $0.00001 per share, of the Company (the “Common Stock”), 0.35 of a series A warrant to purchase one share of Common Stock (“Series A Warrants”) and 0.35 of a series B warrant (“Series B Warrants”) to purchase one share of Common Stock (collectively, the “Warrants”) and/or (ii) an aggregate of 42,857,142 pre-funded units (“Pre-funded Units”) consisting of one pre-funded warrant to purchase one share of Common Stock (the “Pre-funded Warrants”), 0.35 of a Series A Warrant and 0.35 of a Series B Warrant. The Common Units and Pre-funded Units to be sold by the Company to the Underwriter are called the “Firm Securities.” At the option of the Underwriter, the Comp
